XERIS BIOPHARMA HOLDINGS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.4M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $20.9M |
| SG&A Expense | — | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M | $73.7M |
| Operating Income | — | $24.9M | $-33.6M | $-44.0M | $-81.9M | $-115.2M | $-83.5M |
| Operating Margin | — | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -408.8% |
| Interest Expense | — | — | — | $26.6M | $14.1M | $7.2M | $10.7M |
| Pretax Income | — | $554.0K | $-57.1M | $-63.5M | $-96.1M | $-122.7M | — |
| Income Tax Expense | — | $0 | $-2.3M | $-1.2M | $-1.4M | $0 | $-110.0K |
| Net Income | — | $554.0K | $-54.8M | $-62.3M | $-94.7M | $-122.7M | $-91.1M |
| Net Margin | — | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| EPS (Basic) | — | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 |
| EPS (Diluted) | — | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 |
| Shares Outstanding (Basic) | 172.4M | 160.4M | 146.8M | 137.7M | 135.6M | 79.0M | — |
| Shares Outstanding (Diluted) | 172.4M | 172.7M | 146.8M | 137.7M | 135.6M | 79.0M | — |
| Dividends Per Share | — | — | — | — | — | — | — |